Global, regional, and national burden of other musculoskeletal disorders 1990–2017: results from the Global Burden of Disease Study 2017

Rheumatology ◽  
2020 ◽  
Author(s):  
Saeid Safiri ◽  
Ali Asghar Kolahi ◽  
Marita Cross ◽  
Kristin Carson-Chahhoud ◽  
Amir Almasi-Hashiani ◽  
...  
Keyword(s):  
Burden Of Disease ◽  
National Level ◽  
Point Prevalence ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Prevalence Estimates ◽  
National Burden ◽  
Disease Study

Abstract Objectives To describe the level and trends of point prevalence, deaths and disability-adjusted life years (DALYs) for other musculoskeletal (MSK) disorders, i.e. those not covered by specific estimates generated for RA, OA, low back pain, neck pain and gout, from 1990 to 2017 by age, sex and sociodemographic index. Methods Publicly available modelled estimates from the Global Burden of Disease (GBD) 2017 study were extracted and reported as counts and age-standardized rates per 100 000 population for 195 countries and territories between 1990 and 2017. Results Globally, the age-standardized point prevalence estimates and deaths rates of other MSK disorders in 2017 were 4151.1 and 1.0 per 100 000. This was an increase of 3.4% and 7.2%, respectively. The age-standardized DALY rate in 2017 was 380.2, an increase of 3.4%. The point prevalence estimate was higher among females and increased with age. This peaked in the 65–69 year age group for both females and males in 2017, followed by a decreasing trend for both sexes. At the national level, the highest age-standardized point prevalence estimates in 2017 were seen in Bangladesh, India and Nepal. The largest increases in age-standardized point prevalence estimates were observed in Romania, Croatia and Armenia. Conclusion The burden of other MSK disorders is proven to be substantial and increasing worldwide, with a notable intercountry variation. Data pertaining to specific diseases within this overarching category are required for future GBD MSK estimates. This would enable policymakers to better allocate resources and provide interventions appropriately.

scholarly journals Burden of Eating Disorders in China, 1990-2019: An Updated Systematic Analysis of the Global Burden of Disease Study 2019

2021 ◽  
Vol 12 ◽  
Author(s):  
Zhitao Li ◽  
Lili Wang ◽  
Haixia Guan ◽  
Cheng Han ◽  
Peng Cui ◽  
...  
Keyword(s):  
Eating Disorders ◽  
Burden Of Disease ◽  
National Level ◽  
Epidemiological Data ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Systematic Analysis ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Disease Study

Background: Eating disorders, including anorexia nervosa (AN) and bulimia nervosa (BN), are complex mental disorders. A better understanding of the burden of eating disorders is essential for improving their management. Information about the burden of eating disorders at the national level in China remains unclear.Methods: This is a systematic analysis of the Global Burden of Disease Study (GBD) 2019. The sex- and age-specific prevalence, incidence, and disability-adjusted life years (DALYs) of eating disorders in China were estimated by systematically reviewing all available epidemiological data and inputting these data into a Bayesian meta-regression tool (DisMod-MR 2.0). Trends in the age-standardized prevalence, incidence, and DALYs due to AN and BN were assessed from 1990 to 2019.Results: The age-standardized incidence rate (ASIR), prevalence rate (ASPR), and DALY rate per 100,000 population were estimated to be 13.22 (95% UI, 9.35–18.23), 38.08 (95% UI: 26.37–55.73), and 8.38 (95% UI, 4.87–13.35) for AN and 130.05 (95% UI, 84.02–187.13), 75.21 (95% UI, 48.52–105.97), and 16.16 (95% UI, 9.23–25.40) for BN, respectively, in 2019. The prevalence, incidence, and DALY rate of AN peaked at 15–19 years old. The prevalence and DALY rate of BN peaked at 30–34 years old. Females had a higher burden of AN and a lower burden of BN than males. The ASIR, ASPR, and DALY significantly increased by 1.3% (95% CI: 1.3–1.4%), 1.6% (95% CI, 1.5–1.6%), and 1.6% (95% CI, 1.5–1.7%) for AN and 1.4% (95% CI: 1.4–1.4%), 2.0% (95% CI, 2.0–2.1%), and 2.0% (95% CI, 2.0–2.1%) for BN, respectively, from 1990 to 2019 in China. In addition, the increments in all the age-standardized measures of BN were higher in males than in females.Conclusions: The burden of eating disorders in China showed unexpected patterns that varied by sex and age, with increasing trends of AN and BN from 1990 to 2019. More attention should be given to improving the burden of BN in males in China.

scholarly journals India’s Performance in Controlling Visceral Leishmaniasis as Compared to Brazil Over Past Three Decades: Findings From Global Burden of Disease Study

2021 ◽  
Author(s):  
DEEPAK DHAMNETIYA ◽  
Ravi Prakash Jha ◽  
Shalini . ◽  
Krittika Bhattacharyya
Keyword(s):  
Visceral Leishmaniasis ◽  
Burden Of Disease ◽  
Rate Of Change ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Mortality And Morbidity ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Disease Study ◽  
Incidence Prevalence

Abstract Visceral leishmaniasis (VL) is a neglected tropical disease which contributes to the mortality and morbidity significantly in India and Brazil. This study was planned to compare the trends of incidence, prevalence, death and disability-adjusted life years (DALY) of VL burden in India and Brazil from 1990 to 2019 using Global burden of disease study (GBD) data. The metrics are presented as age-standardized rates per 100,000 inhabitants with their respective uncertainty intervals (95%UI) and relative percentages of change. The decline in the Incidence rate is more in case of India (16.82 cases per 100,000 in 1990 to 0.60cases in 2019) as compared to Brazil (3.12 cases per 100,000 in 1990 to 2.65 cases in 2019). The annualized rate of change in number of prevalent cases for India is -0.95 (95% UI, -0.98 to -0.91) whereas for Brazil it is -0.06 (95% UI, -0.41 to 0.52). The annualized rate of change in number of DALY for India is -0.94 (95% UI, -0.96 to -0.92) whereas for Brazil it is -0.09 (95% UI, -0.25 to 0.28). The annualized rate of change in number of deaths for India is -0.93 (95% UI, -0.95 to -0.92) whereas for Brazil it is increasing i.e. 0.04 (95% UI, -0.12 to 0.51). India achieves significant reduction in the age standardized incidence, prevalence, mortality and DALY of VL as compare to Brazil during the period of 1990 to 2019. A multi-centric study is required to assess bottleneck in the existing strategies of VLSCP in Brazil.

scholarly journals Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 global burden of disease study

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Hairong He ◽  
Hongjun Xie ◽  
Yule Chen ◽  
Chengzhuo Li ◽  
Didi Han ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Latin America ◽  
Burden Of Disease ◽  
Western Europe ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Using Data ◽  
Disease Study

Abstract Background The aim of this study is to describe the prevalence and mortality of bladder cancer (BCa) using data obtained in the Global Burden of Disease study performed in 2017 (GBD 2017). Methods Data on BCa for 2017, including prevalence, mortality, and disability-adjusted life years (DALYs), were obtained from GBD 2017 at the global, regional, and national levels. We also analyzed the association of BCa burden with the country development level. Results There were 2.63 million BCa cases estimated from the GBD 2017 data, with 200,000 persons dying of BCa, resulting in 3.60 million DALYs in 2017. The age-standardized prevalence (ASP) of BCa was 32.91/100,000 persons, and age-standardized death rate (ASDR) was 2.57/100,000 persons. The ASP and ASDR of BCa were higher in males than in females, and higher in people older than 60 years. The ASP and ASDR of BCa were higher in Western Europe and Central Europe than in South Asia, Andean Latin America, and Central Latin America, and higher in countries with a higher sociodemographic index (SDI). Correlation analysis identified that the ASP and ASDR of BCa were positively correlated with the country SDI (P < 0.0001 and ρ = 0.68 for ASP, and P = 0.0048 and ρ = 0.20 for ASDR). In addition, 33.72% deaths and 36.80% DALYs caused by BCa could be attributed to smoking globally. Conclusion The prevalence and mortality of BCa were very high in 2017, especially in high-SDI countries. Smoking-cessation strategies should be strengthened to control the burden associated with BCa.

The prevalence and burden of mental and substance use disorders in Australia: Findings from the Global Burden of Disease Study 2015

2018 ◽  
Vol 52 (5) ◽  
pp. 483-490 ◽  
Author(s):  
Liliana G Ciobanu ◽  
Alize J Ferrari ◽  
Holly E Erskine ◽  
Damian F Santomauro ◽  
Fiona J Charlson ◽  
...  
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Burden Of Disease ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Years Of Life Lost ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Disease Study ◽  
Years Lived With Disability

Objectives: Timely and accurate assessments of disease burden are essential for developing effective national health policies. We used the Global Burden of Disease Study 2015 to examine burden due to mental and substance use disorders in Australia. Methods: For each of the 20 mental and substance use disorders included in Global Burden of Disease Study 2015, systematic reviews of epidemiological data were conducted, and data modelled using a Bayesian meta-regression tool to produce prevalence estimates by age, sex, geography and year. Prevalence for each disorder was then combined with a disorder-specific disability weight to give years lived with disability, as a measure of non-fatal burden. Fatal burden was measured as years of life lost due to premature mortality which were calculated by combining the number of deaths due to a disorder with the life expectancy remaining at the time of death. Disability-adjusted life years were calculated by summing years lived with disability and years of life lost to give a measure of total burden. Uncertainty was calculated around all burden estimates. Results: Mental and substance use disorders were the leading cause of non-fatal burden in Australia in 2015, explaining 24.3% of total years lived with disability, and were the second leading cause of total burden, accounting for 14.6% of total disability-adjusted life years. There was no significant change in the age-standardised disability-adjusted life year rates for mental and substance use disorders from 1990 to 2015. Conclusion: Global Burden of Disease Study 2015 found that mental and substance use disorders were leading contributors to disease burden in Australia. Despite several decades of national reform, the burden of mental and substance use disorders remained largely unchanged between 1990 and 2015. To reduce this burden, effective population-level preventions strategies are required in addition to effective interventions of sufficient duration and coverage.

scholarly journals The disvalue of death in the global burden of disease

2017 ◽  
Vol 44 (3) ◽  
pp. 192-198 ◽  
Author(s):  
Carl Tollef Solberg ◽  
Ole Frithjof Norheim ◽  
Mathias Barra
Keyword(s):  
Burden Of Disease ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Years Of Life Lost ◽  
Loss Of Life ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Life Itself ◽  
Disease Study ◽  
Years Lived With Disability

In the Global Burden of Disease study, disease burden is measured as disability-adjusted life years (DALYs). The paramount assumption of the DALY is that it makes sense to aggregate years lived with disability (YLDs) and years of life lost (YLLs). However, this is not smooth sailing. Whereas morbidity (YLD) is something that happens to an individual, loss of life itself (YLL) occurs when that individual’s life has ended. YLLs quantify something that involves no experience and does not take place among living individuals. This casts doubt on whether the YLL is an individual burden at all. If not, then YLDs and YLLs are incommensurable. There are at least three responses to this problem, only one of which is tenable: a counterfactual account of harm. Taking this strategy necessitates a re-examination of how we count YLLs, particularly at the beginning of life.

scholarly journals Global, regional and national burden of gout, 1990–2017: a systematic analysis of the Global Burden of Disease Study

Rheumatology ◽  
2019 ◽  
Vol 59 (7) ◽  
pp. 1529-1538 ◽  
Author(s):  
Yang Xia ◽  
Qijun Wu ◽  
Hanyuan Wang ◽  
Shuang Zhang ◽  
Yuting Jiang ◽  
...  
Keyword(s):  
Burden Of Disease ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Disability Adjusted Life Years ◽  
Annual Percent Change ◽  
Percent Change ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Study Results ◽  
Disease Study

Abstract Objectives The burden of gout has been increasing globally. However, little is known about the global, regional and national distribution and time trend of this disease. We present a comprehensive analysis of the Global Burden of Disease Study 2017 on gout burden estimates for 195 countries or territories between 1990 and 2017. Methods Age-standardized prevalence and disability-adjusted life-years of gout were reported between 1990 and 2017 in 195 countries and territories, and associations between these estimates and sociodemographic index (SDI) were further explored. Total and annual percent change between 1990 and 2017 were calculated to quantify the time trends of gout burden. Results Age-standardized prevalence rates (95% uncertainty interval) per 100 000 persons were 790.90 (706.10–881.90) and 253.49 (225.69–284.02) in 2017 in males and females, respectively. The annual percent change in age-standardized prevalence (males, 0.22%; females, 0.38%) and disability-adjusted life-years (males, 0.21%; females, 0.38%) of gout increased every year from 1990 to 2017, globally. The highest increase was detected in high-SDI countries, especially in high-income North America. A non-linear association was observed between burden of gout and SDI, with the lowest estimates of gout burden when SDI value was about 0.6. High BMI was the leading risk factor for the burden of gout. Conclusion These study results suggest a globally rising trajectory of gout burden between 1990 and 2017. More effective interventions, such as detailed and intensive dietary managements and other prevention strategies for reducing obesity, should be carried out to reverse this trend, especially in females and high-SDI countries.

Sign in / Sign up

Export Citation Format

Share Document